Molecular or Immunoassay? Which Technology Will Win the Race for the Point of Care Diagnostics Market?
ROCKVILLE, Md., April 12, 2017 /PRNewswire/ -- Kalorama said that new technologies in the point-of-care diagnostics market pit molecular against immunoassays in an interesting way. The healthcare market researcher with a specialty in the IVD market said that as molecular diagnostics enter point-of-care (POC) settings, cost becomes a key issue in comparison to predominantly used and cheaply performed rapid immunoassays. In routine testing applications such as screening, test cost is often prioritized over performance, especially in low-resource health systems. High-burden tropical diseases in the developing world such as malaria represent a significant opportunity for molecular tests in the POC diagnostic market, but must displace or compete against rapid immunoassays in established screening programs or future initiatives. Significant cost reductions will be necessary for molecular diagnostics to penetrate such markets, and only then may be limited to relatively niche applications. Kalorama Information's report, The Market and Potential for Molecular Point of Care Diagnostics, defines markets for testing for several categories of tests.
The sensitivity and specificity of nucleic acid analytes provide molecular diagnostics key advantages in clinical practice, particularly in critical health situations." said Kalorama IVD analyst Emil Salazar on a recent blog post. "Nucleic acid amplification, or molecular tests, are now open to routine and distributed use in healthcare thanks to advancements in microfluidics and molecular reagents"
Emblematic in terms of where the infectious disease POC testing market is heading and the competitive challenges awaiting molecular POC products, rapid test specialist Chembio Diagnostics recently announced plans to develop a single test for 9 febrile illnesses. Multiplex testing of infections with similar symptoms or Syndromic panel testing is increasingly used in healthcare to quickly diagnose patients during admission and initiation of care. Developing a single test on an immunoassay format would be an achievement in rapid syndromic testing, and available at potentially a fraction of the cost for rapid molecular tests. Chembio will collaborate with the Geneva-based Foundation for Innovative New Diagnostics (FIND) to develop a multiplex rapid immunoassay for malaria, dengue fever, Zika virus, chikungunya, leptospirosis, Rikettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. The Chembio DPP Fever Panel is intended for syndromic panel testing in the Asia-Pacific region.
Rapid malaria tests represent the highest volume test market in the developing world with over 300 million tests procured annually, an estimated global need for over 1 billion tests annually, and over 3 billion people at risk for infection. The average test costs something in the range of $0.35-0.50 depending upon its ability to detect P. falciparum only or multiple malaria pathogens. Market consolidation has also been a strong pricing factor with only two principal manufacturers, Standard Diagnostics (Alere) and Access Bio with Premier Medical Corporation (PMC). Distribution of a multiplex assay such as Chembio's Fever Panel will be difficult to achieve at the scale of rapid malaria assays, even if other specialized disease panels were developed for other regions. The added cost of a multiplex panel will make displacement of cheap malaria assays very difficult, but panels should find lower volume usage as a follow-up test to negative results for malaria.
In Kalorama Information's molecular POC diagnostics report, molecular syndromic panels for tropical and neglected diseases were estimated to have an achievable market of approximately $25 million by 2020, but only at a price point of $20 or less per test. The market opportunity may be even slighter if competitors such as Chembio introduce cheaper multiplex immunoassays. Kalorama Information's report contains dozens of other market data points and segment market size estimates and forecasts. The report is available at: https://www.kaloramainformation.com/Potential-Molecular-Point-9858007/
For more Kalorama reports on diagnostics visit:
https://www.kaloramainformation.com/diagnostics-market-c1125/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
Share this article